Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - News - Generic Drugs - March 23, 2019

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/18 - Teva Announces US Launch of a Generic Version of Elidel
Teva Pharmaceutical Industries today announced the launch of a generic version of Elidel Cream, 1% in the U.S.. As quoted in the press release:. The post Teva Announces US Launch of a Generic Version of Elidel appeared first on Investing News Network.
12/29/18 - Animal Generic Drug Market Research Report 2018-2025 by Prominent Players Are Bayer Animal Health, Bimeda, Boehringer Ingelheim: The competitor research carried out accumulates information about both the existing as well as potential competitors oper
New York, NY 12/28/2018 The latest research report on Animal Generic Drug market for the forecast period, 2018- 2025 is involved in screening the business environment and the companies operating in the Animal Generic Drug industry. Importantly, the research sheds a lot of light on their winning strategies to help stakeholders, business owners
12/29/18 - Follow-on Biologics Market Qualitative Analysis Reveals Explosive Growth by 2018-2025: Sandoz, Pfizer, Teva Pahrmaceutical, Celltrion, Biocon, Amgen: A closer look at the aspects including but not limited to Follow-on Biologics market segmentation by
New York, NY 12/29/2018 A new market assessment report on the Follow-on Biologics market provides a comprehensive overview of the Follow-on Biologics industry for the forecast period 2018- 2025. The analytical study is proposed to provide immense clarity on the market size, share and growth rate across different regions. The major players cov
12/28/18 - Amgen Submits Biologics License Application for ABP 710 Biosimilar Infliximab To US Food And Drug Administration
By a News Reporter-Staff News Editor at Pharma Business Week Amgen announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for ABP 710, a biosimilar candidate to REMICADE . "At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We're leveraging
12/28/18 - Aurobindo`s injectable business grows 8% year-on-year to $50 mn in Q2 [Sudan Tribune]
Hyderabad-headquartered Aurobindo Pharmaceuticals, which draws around 47 per cent of its revenues from the US, is a late entrant in the biosimilars and injectables space. In comparison, Aurobindo USA, the company that markets oral formulations in the US has witnessed a decline of 11 per cent year-on-year on a high base in the second quarter.
12/28/18 - Bio-Thera Solutions Files IND for Phase 1 Clinical Trial with BAT8003 (Trop2-ADC) as Treatment for Trop2 Positive Cancers [Syrian Arab News Agency]
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has filed an Investigational New Drug Application with the China National Medical Products Administration for the Company`s anti-Trop2 Antibody-Drug Conjugate, BAT8003, as a...
12/28/18 - Dr. Reddy's Laboratories announces the launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market
Hyderabad- Dr. Reddy's Laboratories Ltd. today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela for Oral Suspension, approved by the U.S. Food and Drug Administration. Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to pr
12/28/18 - Launch of Generic Lialda Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering
By a News Reporter-Staff News Editor at Pharma Business Week Global pharmaceutical company Mylan N.V. announced the U.S. launch of Mesalamine Delayed-Release Tablets USP, 1.2 g, a generic version of Shire' s Lialda Delayed-Release Tablets. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration for its Abbrevia
12/28/18 - Mylan Adds First Generic for Canasa Rectal Suppository to Growing Gastroenterology Portfolio
By a News Reporter-Staff News Editor at Pharma Business Week Global pharmaceutical company Mylan N.V. announced the U.S. launch of Mesalamine Rectal Suppository, 1000 mg, the first generic version of Allergan's Canasa Rectal Suppository, 1000 mg. Mylan Pharmaceuticals received final approval from the U.S. Food and Drug Administration for its A
12/28/18 - Supply Medicines/drugs/dressings/consumables On Day To Day Basis For Esic Model Hospital, Baddi For The Period 2018-20 Branded Drugs (a) Generic Drugs (b) [TendersInfo (India)]
Tenders are invited for Supply medicines/drugs/dressings/Consumables on day to day basis for ESIC Model Hospital, Baddi for the period 2018-20 Branded drugs Generic drugs EMD value: INR 30000 Major organization: EMPLOYEES STATE INSURANCE CORPORATION Address: Village- Katha, Baddi, Solan 173205 Himachal Pradesh Country: India Url:...
12/28/18 - Teva Announces US Launch of a Generic Version of Elidel Cream, 1%
JERUSALEM- Teva Pharmaceutical Industries Ltd., today announced the launch of a generic version of Elidel1 Cream, 1% in the U.S.. With over 550 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-file
12/27/18 - Bio-Thera Solutions Files IND forPhase 1 Clinical Trial with BAT8003 (Trop2-ADC) as Treatment for Trop2 Positive Cancers
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has filed an Investigational New Drug Application with the China National Medical Products Administration for the Company's anti-Trop2 Antibody-Drug Conjugate, BAT8003, as a...
12/27/18 - Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd. today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela for Oral Suspension, approved by the U.S. Food and Drug Administration. The Renvela brand and generic had U.S. sales of approxim
12/27/18 - Dr. Reddy's Labs Unveils Renvela Generic Sevelamer Carbonate In U.S
PARIS- Dr. Reddy's Laboratories Ltd. announced Thursday the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets. It is a therapeutic equivalent generic version of Renvela for Oral Suspension, approved by the U.S. Food and Drug Administration. Dr. Eddy's noted that the Renvela brand and generic had U.S. sales of approximate
12/27/18 - Global Biosimilars Market Insight Analysis Report on Size, Revenue, Share and Volume Overview 2017-2026: Biosimilars can be made only when the patent for the original biologic medical product expires. Regulatory authorities approve biosimilars only a
New York, NY 12/26/2018 Global Biosimilars Market Survey 2018 presented by MarketResearch.Biz integrates concise analysis and exhaustive presentation of logical data together. The industrial aspects are thoroughly characterizing on both global and regional scales. Amgen Inc Biocon Ltd Celltrion Inc Dr. Reddy's Laboratories Mylan Inc Pfizer In
12/27/18 - Global Biosimilars Market Insight Growth Analysis on Volume, Revenue, Share and Size Forecast to 2017-2026: Biosimilars can be made only when the patent for the original biologic medical product expires. Regulatory authorities approve biosimilars onl
New York, NY 12/27/2018 Global Biosimilars Market Survey 2018 presented by MarketResearch.Biz integrates concise analysis and exhaustive presentation of logical data together. The industrial aspects are thoroughly characterizing on both global and regional scales. Amgen Inc Biocon Ltd Celltrion Inc Dr. Reddy's Laboratories Mylan Inc Pfizer In
12/27/18 - Supply Of Generic Drugs To Taluk Hospital Bantwal. [TendersInfo (India)]
Tenders are invited for Supply of generic drugs to taluk hospital bantwal. Last Date& Time for receipt of tenders: 09/01/2019 17:00: 00. Date& Time for Opening of Technical Bid: 11/01/2019 09:30: 00 Major organization: DIRECTORATE OF HEALTH AND FAMILY WELFARE SERVICES Address: Attn: Cmo Bantwal Country: India Tender notice number: DHFWS/2018-19/IND
12/27/18 - Teva agrees settlement with Neos on ADHD drug [Globes, Tel Aviv, Israel]
Dec. 27 Teva, Celltrion win FDA approval for Rituxan biosimilar. Teva begins selling generic EpiPen. Visit the Globes at www.globes.co.il/serveen/globes/nodeview. asp?
12/27/18 - Teva and Bausch Health: Very Deep Value From Here
If at least 16 companies and their 300 drugs are under review for alleged price-fixing, then the slump in shares of Teva Pharmaceuticals and Bausch Health could last a while longer. Endo International plc is not doing any better. Bausch Health fell in sympathy for the sell-off in generic drug companies.
12/27/18 - Teva Announces US Launch of a Generic Version of Elidel (Pimecrolimus) Cream, 1%
Teva Pharmaceutical Industries Ltd., today announced the launch of a generic version of Elidel 1 Cream, 1% in the U.S.. With over 550 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in th
12/27/18 - Trade deal with Canada, Mexico could delay arrival of cheaper generic drugs, critics warn
WASHINGTON Makers of expensive brand-name drugs scored a victory when the U.S.' s new trade deal with Canada and Mexico included language preventing generic copies of their prescription medicines from hitting shelves for at least a decade. "This trade agreement, if left in its current form, will keep drug prices high in the United States to the de
12/26/18 - CATALYST PHARMACEUTICALS, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Financial Statements and Exhibits
On December 18, 2018, Catalyst Pharmaceuticals, Inc. and Endo Ventures Limited entered into that certain Development, License and Commercialization Agreement. Pursuant to the Agreement, Endo will further develop and commercialize generic Sabril tablets through Endo's U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical.
12/26/18 - Genereic plan more placebo than cure
Over the past decade or so, the market for generic drugs has become, as research chemist Derek Lowe puts it, more and more deranged. Prices of boring old drugs, off patent for decades, have experienced the kind of breathtaking spikes and dizzying crashes that are usually reserved for exotic financial instruments. Scott Gottlieb, the Food and
12/26/18 - Neos Reaches Settlement With Teva On Cotempla XR-ODT Patent Litigation
PETAH TIKVA- Neos Therapeutics Inc. said that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA Inc. to resolve all ongoing litigation involving Neos' patents protecting its Cotempla XR-ODT extended-release orally disintegrating tablets and Teva's Abbreviated New Drug Application or ANDA filed with.
12/26/18 - PharmSource - Catching the Next Wave-How Much Have CMOs Benefited from Biosimilars-2018 Edition
PharmSource-Catching the Next Wave: How Much Have CMOs Benefited from Biosimilars-2018 Edition Summary Biosimilars are drugs that are highly similar but not identical to branded "innovator" biologics: large molecule,...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415